ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keles, C.
Right arrow Articles by Yakut, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keles, C.
Right arrow Articles by Yakut, C.
Related Collections
Right arrow Valve disease

Ann Thorac Surg 2001;71:1160-1163
© 2001 The Society of Thoracic Surgeons

Original article: cardiovascular

Surgical treatment of brucella endocarditis

Cüneyt Keles, MDa, Nilgün Bozbuga, MDa, Mesut Sismanoglu, MDa, Mustafa Güler, MDa, Hasan Basri Erdogan, MDa, Esat Akinci, MDa, Cevat Yakut, MDa

a Kouyolu Heart and Research Hospital, stanbul, Turkey

Accepted for publication November 28, 2000.

Address reprint requests to Dr Bozbuga , Kosuyolu Heart and Research Hospital, 81020 Kadiköy, Istanbul, Turkey
e-mail: kosuyolu{at}superonline.com

Background. Brucella endocarditis (BE) is a lethal complication of human brucellosis, which is rarely seen and hardly described.

Methods. In the present report, six successfully treated cases of BE involving three native aortic valves, two native mitral-aortic valves, and a mitral bioprosthesis are described. The diagnosis of BE was based on clinical features, high brucella serologic titers, and positive blood cultures. Although the blood cultures were positive in all patients, all the resected valve materials and tissue cultures were negative. The patients received rifampicin, streptomycin, and doxycycline (in 3 patients), rifampicin, tetracycline, and cotrimoxazole (in 2 patients), and rifampicin, doxycycline, and cotrimoxazole (in 1 patient). Infected native valves and bioprosthesis were replaced by mechanical valves.

Results. There was no early or late mortality. No recurrent infection developed after management with a combination of antibiotherapy lasting 6 months postoperatively during a mean follow-up of 47 months (range 20 to 84 months).

Conclusions. This report suggests that the combination of valve replacement and antibiotic therapy produces successful results in the treatment of BE.




This article has been cited by other articles:


Home page
 Trop DoctHome page
Y. Gunes, M. Tuncer, U. Guntekin, S. Akdag, H. A. Gumrukcuoglu, M. Karahocagil, and H. Ekim
Clinical characteristics and outcome of Brucella endocarditis
Trop Doct, April 1, 2009; 39(2): 85 - 88.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
H. Sunar and E. Duran
Vegetectomy in brucella endocarditis
Ann. Thorac. Surg., June 1, 2002; 73(6): 2036 - 2036.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2001 by The Society of Thoracic Surgeons.